Showing results (341-350 of 399) with videos related to

Sort By:
Pageof 40
British Journal of Haematology|August 12, 2015
Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphomaDai Chihara, Barbara Pro, Sanam Loghavi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|January 10, 2006
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresisKouhei Yamashita, Mitchell E Horwitz, Akua Kwatemaa, et al.
Cancer|June 29, 2016
Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphomaDai Chihara, Jason R Westin, Yasuhiro Oki, et al.
Stem Cells (Dayton, Ohio)|December 24, 2014
Bone marrow-derived mesenchymal stromal cells harness purinergenic signaling to tolerize human Th1 cells in vivoShoba Amarnath, Jason E Foley, Don E Farthing, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 20, 2016
Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomesC Y Cheah, D Chihara, S Horowitz, et al.
Blood Advances|June 15, 2025
A phase 2 study of obinutuzumab combined with lenalidomide in previously untreated high tumor burden follicular lymphomaNeha Akkad, Lei Feng, Jason R Westin, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.
Blood Advances|August 16, 2022
Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphomaGilles Salles, Stephen J Schuster, Martin Dreyling, et al.
Leukemia|October 19, 2011
Clinical laboratory markers of inflammation as determinants of chronic graft-versus-host disease activity and NIH global severityL Grkovic, K Baird, S M Steinberg, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 29, 2016
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized TrialsQian Shi, Christopher R Flowers, Wolfgang Hiddemann, et al.
Pageof 40